-
Pharmaceutical companies have been positive in consistency evaluation, and a large number of drugs have been evaluated within a week
Time of Update: 2022-10-01
Chinese medicine cefotaxime sodium review Chinese medicine cefotaxime sodium review China Pharmaceutical announced on September 23 that GM Sanyo, a wholly-owned subsidiary of the company, received two copies of the "Notice of Approval of Drug Supplement Application for Drug Supplementation" issued by the State Food and Drug Administration for injection of cefotaxime sodium, which passed the consistency evaluation of generic drug quality and efficacy.
-
Nearly 70% of A-share companies have pre-performed in the third quarter, focusing on chemical, new energy, pharmaceutical and other fields
Time of Update: 2022-10-01
For example, on September 19, Kaipu Bio released the first three quarters of 2022 performance forecast, during the reporting period, the net profit attributable to the shareholders of the listed company is expected to be 1.
-
Notice of the State Food and Drug Administration on the Publication of the Catalogue of Generic Drug Reference Preparations (46th Batch) (No. 82 [2021])
Time of Update: 2022-10-01
doc to Notice No. 82 [2021] of the State Drug Administration After the review and confirmation of the Expert Committee on the Consistency Evaluation of Generic Drugs and Efficacy of the State Drug Administration, the Catalogue of Generic Drug Reference Preparations (46th Batch) is hereby published.
-
The enthusiasm for the research and development of innovative drugs in traditional Chinese medicine is high, and new progress is constantly made!
Time of Update: 2022-09-30
For example, Kangchen Pharmaceutical recently announced that the company's phase III clinical trial of the company's innovative Chinese medicine golden herb tablets for the treatment of chronic pelvic pain in pelvic inflammatory diseases has obtained ethical review approval, and the current research of the project is progressing smoothly, and it is expected to complete the first case of subject enrollment in the near future.
-
Zhejiang reference preparation (original research drug) hanging network procurement information combing results are announced
Time of Update: 2022-09-30
, Ltd. bid for, namely Beijing, Hebei, Henan, Hubei, Hunan, Jiangsu, Shandong, Sichuan, Tianjin and Yunnan, with a minimum difference ratio unit price of 260 yuan.
, Ltd. bid for, namely Beijing, Hebei, Henan, Hubei, Hunan, Jiangsu, Shandong, Sichuan, Tianjin and Yunnan, with a minimum difference ratio unit price of 260 yuan.
-
The development of improved new drugs is accelerating into the "fast lane"!
Time of Update: 2022-09-30
On June 15, Jiudian Pharmaceutical announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the State Drug Administration for the improved new drug PDX-03, and will carry out clinical trial research after completing the relevant preparatory work.
-
The balance of 2022 is 100 days, how many goals have been achieved by major pharmaceutical machinery companies at the beginning of the year?
Time of Update: 2022-09-30
It is worth mentioning that the performance of ROMACO in the first half of the year is not satisfactory, and the semi-annual report shows that during the reporting period, Romaco achieved operating income of 531 million yuan in the first half of the year, down 23.
-
In the first half of the year, the Chinese medicine industry achieved double growth in revenue and net profit, and the performance of Chinese medicine tablets was particularly eye-catching
Time of Update: 2022-09-30
National pharmaceutical industry statistics show that in the first half of 2022, the traditional Chinese medicine industry achieved steady growth, with revenue reaching 340.
National pharmaceutical industry statistics show that in the first half of 2022, the traditional Chinese medicine industry achieved steady growth, with revenue reaching 340.
-
The overall R&D expense rate of the pharmaceutical industry continues to rise, and these high-input pharmaceutical companies have received intensive institutional research
Time of Update: 2022-09-30
In the first half of this year, the total R&D investment of Healthy Yuan was 805 million yuan, an increase of 15.
In the first half of this year, the total R&D investment of Healthy Yuan was 805 million yuan, an increase of 15.
-
Innovative drug hematopoiesis is accelerating the transformation of traditional pharmaceutical companies!
Time of Update: 2022-09-30
Judging from the data of Hansen Pharmaceutical in the past three years, its innovative drug revenue has increased from 752 million yuan in H1 in 2020 to 2.
-
Kangyuan Pharmaceutical focuses on the research and development of new drugs, and the price of raw materials such as Zhejiang shellfish has increased!
Time of Update: 2022-09-30
Table 1: List of exclusive products of Kangyuan Pharmaceutical According to Intranet data, in 2021, the sales of apricot shell cough granules in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 90 million yuan, an increase of 61.
-
Another innovative Chinese medicine drug was approved for listing! From Wuhan Pharmaceutical Company
Time of Update: 2022-09-30
【Pharmaceutical Network Industry News】Recently, the State Food and Drug Administration approved the listing registration application of Wuhan Guanggu Renfu's class 1. 2 class of traditional Chinese me
-
Due to the production and marketing of non-compliant chrysanthemums, the pharmaceutical company ate nearly 600,000 yuan fine!
Time of Update: 2022-09-30
The Anhui Provincial Food and Drug Administration also recently issued a notice that a Chinese medicine tablet company in Bozhou City was fined nearly 600,000 yuan for producing and selling chrysanthemums that did not meet the regulations.
-
Local innovative drug companies join forces to actively explore clinical value!
Time of Update: 2022-09-30
In China, the drug has completed two Phase III clinical studies of duodenal ulcer and gastroesophageal reflux, and submitted a marketing application for 2 indications to the State Food and Drug Administration in September 2021, and is currently undergoing review and approval.
-
The deputy general manager of a pharmaceutical company with an annual salary of 600,000 yuan resigned!
Time of Update: 2022-09-30
【Pharmaceutical Network Industry News】On September 24, Wellcome Pharmaceutical issued an announcement that the company's board of directors received a written resignation report submitted by Mr. Lie Jianle, deputy general manager of the company, on September 22, 2022, and Mr. Lie Jianle applied to resign as deputy general manager of the company for personal reasons (the original term of office was until May 16, 2024).
-
The 2022 Pharmaceutical & Medical Device Digital Innovation Conference and Star Medical Award was successfully concluded in Shanghai
Time of Update: 2022-09-30
The "2022 Pharmaceutical & Medical Device Digital Innovation Conference & Star Medical Award Ceremony" hosted by Qiguan Information and Feiyu Business was held on September 21, 2022 in the banquet ha
-
Within a week, the listing applications of a number of pharmaceutical companies for APIs were approved
Time of Update: 2022-09-30
In recent years, with the advancement of collection policies, consistency evaluation and drug-related approval, as well as the impact of factors such as the transfer of global orders, the scale of China's API industry is continuing to expand.
-
In September, pharmaceutical companies ushered in a "resignation boom", involving chairman and vice president
Time of Update: 2022-09-30
China Resources Shuanghe: Director Resignation On September 8, China Resources Shuanghe announced that the company recently received the resignation report submitted by Ms. Weng Jingwen, who applied to resign as a director of the ninth board of directors and a member of the special committee of the company due to work arrangements.
-
More than 18 billion antidepressant market has attracted a large number of domestic pharmaceutical companies to seize the beach!
Time of Update: 2022-09-30
In China, according to the website information of the State Food and Drug Administration, there are 3 manufacturers of paroxetine hydrochloride enteric-coated extended-release tablets that have been approved for listing in Chinese mainland, including Fuyuan Pharmaceutical.
-
The performance of the Chinese medicine sector is clearly differentiated, and the net profit of more than 10 Chinese medicine companies in the first half of the year increased by more than 10%
Time of Update: 2022-09-30
On August 24, Panlong Pharmaceutical released its 2022 interim report, which showed that it achieved revenue of 431 million yuan in the first half of the year, an increase of 7.
